Evidence map›Paper›PMID 39976267›Full record

ArticleBioanalysis2025

Development and qualification of an LC-MS/MS method for quantification of MUC5AC and MUC5B mucins in spontaneous sputum.

Weiwen Sun, Si Mou, Catherine Huntington, Helen Killick, Ian Christopher Scott, Aoife Kelly, Monica Gavala, Jessica Larsson, Mani Deepika Vakkalanka, Neil E Alexis and 7 more

Abstract read
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Weiwen SunIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.ORCID 0000-0002-8999-3103
Si MouIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.
Catherine HuntingtonBiologics Engineering, R&D, AstraZeneca, Cambridge, USA.ORCID 0000-0003-3193-9320
Helen KillickTranslational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, R&D, AstraZeneca, Cambridge, UK.
Ian Christopher ScottTranslational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, R&D, AstraZeneca, Cambridge, UK.
Aoife KellyTranslational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, R&D, AstraZeneca, Cambridge, UK.
Monica GavalaTranslational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, R&D, AstraZeneca, Gaithersburg, MA, USA.
Jessica LarssonTranslational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, R&D, AstraZeneca, Cambridge, UK.
Mani Deepika VakkalankaChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.
Neil E AlexisCenter for Environmental Medicine Asthma and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Walter WileyChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.
Aaron WheelerChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.
Kumar ShahChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.
Moucun YuanChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.
William R MylottChromatographic Services - Research & Development Biologics by LC-MS/MS, PPD Laboratory Services (A part of Thermo Fisher Scientific), Richmond, VA, USA.ORCID 0000-0001-7512-2131
Kévin ContrepoisIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.ORCID 0000-0001-9678-5161
Anton I RosenbaumIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.ORCID 0000-0003-1939-951X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAirway mucins in sputum are promising respiratory disease biomarkers, despite posing substantial analytical challenges due to their physicochemical properties and rare and heterogenous nature of the matrix. We aimed to identify a suitable sputum collection and processing method, and qualify a bioanalytical method for MUC5AC and MUC5B quantification in clinical samples.

methodMucins were quantified in induced and spontaneous sputum collected from the same COPD patients, following various sample processing procedures. LC-MS/MS method used truncated recombinant mucins as surrogate analytes in surrogate matrix.

resultsFrozen spontaneous sputum was found to be a suitable and convenient matrix for mucin quantification and fit-for-purpose method qualification was performed.

conclusionOur methodology provides accurate and reliable MUC5AC and MUC5B quantification and facilitates multi-site clinical sputum collection.

Indexed as

Mucin 5ACMucin-5BSputumTandem Mass SpectrometryChromatography, LiquidHumansLiquid Chromatography-Mass SpectrometryPulmonary Disease, Chronic ObstructiveMUC5AC protein, humanMUC5B protein, humanMucin 5ACMucin-5Bbioanalytical methodLC-MS/MSmethod qualificationMUC5ACMUC5Bsputum collectionsputum processing

Identifiers

PMID39976267
PMCPMC11853556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.